Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2…

Overview of attention for article published in Arthritis Research & Therapy, December 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

news: 2 news outlets

twitter: 6 X users

Citations

dimensions_citation: 31 Dimensions

Readers on

mendeley: 104 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 2 news stories from 2 outlets.

PASDAS: Targeting Multiple Aspects of PsA

Medical Health News, 10 Dec 2018

Treatment with secukinumab (Cosentyx) led to sustained remission or low disease activity using a novel, stringent outcome…

PASDAS: Targeting Multiple Aspects of PsA

MedPage Today, 10 Dec 2018

Treatment with secukinumab (Cosentyx) led to sustained remission or low disease activity using a novel, stringent outcome…